Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DFBTA is a highly effective and orally active inhibitor of ANO1, specifically the calcium-activated chloride channel anoctamin-1. It exhibits potent inhibitory activity, with an IC 50 of 24 nM. Notably, DFBTA demonstrates significant analgesic efficacy in treating inflammatory pain [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 1,520.00 | |
50 mg | 10-14 weeks | $ 1,980.00 | |
100 mg | 10-14 weeks | $ 2,500.00 |
Description | DFBTA is a highly effective and orally active inhibitor of ANO1, specifically the calcium-activated chloride channel anoctamin-1. It exhibits potent inhibitory activity, with an IC 50 of 24 nM. Notably, DFBTA demonstrates significant analgesic efficacy in treating inflammatory pain [1]. |
In vitro | DFBTA exhibits minimal cytotoxicity and cardiotoxicity, as indicated by its weak impact on HEK293 proliferation and hERG activity, both with IC50 values exceeding 30 μM [1]. |
In vivo | DFBTA, administered to C57BL/6 mice in doses ranging from 40-80 mg/kg orally (IG) and 40 mg/kg intravenously (IV), exhibits low acute toxicity as evidenced by a minimum lethal dosage (MLD) exceeding 1000 mg/kg. When given orally at a dose of 1000 mg/kg, DFBTA demonstrates superior pharmacokinetic properties, including an oral bioavailability greater than 75% and minimal brain penetration (less than 1.5% brain/plasma ratio) [1]. |
Molecular Weight | 393.79 |
Formula | C18H10ClF2NO3S |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.